This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

Memantine for AIDS dementia complex: open-label report of ACTG 301


Zhao, Yu, Navia, Bradford A., Marra, Christina M., Singer, Elyse J., Chang, Linda, Berger, Joseph, Ellis, Ronald J., Kolson, Dennis L., Simpson, David, Miller, Eric N., Lipton, Stuart A., Evans, Scott R., Schifitto, Giovanni


HIV Clinical Trials, Volume: 11, No.: 1, Pages.: 59-67

Year of Publication



Objective: To evaluate the long-term safety and efficacy of memantine use as treatment of HIV-associated cognitive impairment.; Background: The results of a 20-week, randomized, double-blind, placebo-controlled trial of memantine in HIV-infected participants with cognitive impairment (ACTG 301) were previously reported. We report the results of the up-to-60-week open-label phase following the double-blind phase.; Method: Participants received open-label memantine and were escalated to a 40 mg/day dose or their maximum tolerated dose in the double- blind phase. Adverse experiences were used to evaluate safety, and changes in the mean of eight neuropsychological test scores (NPZ-8) were used to evaluate efficacy.; Results: Ninety-nine participants entered the initial 12-week open-label phase and 45 in the additional 48-week extension. Twenty-seven participants reported severe adverse experiences. During the initial 12-week open-label phase, participants randomized to memantine in the double-blind phase had a statistically significant higher improvement in NPZ-8 compared to those randomized to placebo in the double-blind phase. No statistically significant NPZ-8 changes were detected during the 48-week extension.; Conclusion: Long-term use of memantine appears safe and tolerable. Future randomized studies with longer follow-up are necessary to establish efficacy of memantine for the treatment of HIV-associated cognitive impairment.;

Bibtex Citation

@article{Zhao_2010, doi = {10.1310/hct1101-59}, url = {}, year = 2010, month = {feb}, publisher = {Informa {UK} Limited}, volume = {11}, number = {1}, pages = {59--67}, author = {Yu Zhao and Bradford A. Navia and Christina M. Marra and Elyse J. Singer and Linda Chang and Joseph Berger and Ronald J. Ellis and Dennis L. Kolson and David Simpson and Eric N. Miller and Stuart A. Lipton and Scott R. Evans and Giovanni Schifitto}, title = {Memantine for {AIDS} Dementia Complex: Open-Label Report of {ACTG} 301}, journal = {{HIV} Clinical Trials} }


administration & dosage, adult, adverse effects, aids dementia complex, dopamine agents, double-blind method, drug therapy, female, hivdementia, humans, male, medication, memantine, middle aged, neuropsychological tests, psychology, statistics nonparametric, tolerability

Countries of Study


Types of Study

Cohort Study

Type of Outcomes


Type of Interventions

Pharmaceutical Interventions

Pharmaceutical Interventions

Anti-Alzheimer medications, e.g.: donezepil, galantamine, rivastigmine, memantime